Approximately 30% of acute myeloid leukemias (AML) carry poor prognosis FLT3 mutations, most commonly internal tandem duplications (ITD) that constitutively activate kinase activity and aberrant signaling via STAT5 to promote proliferation and survival [125,126]. The gene discussed is FLT3; the disease is acute myeloid leukemia.